Vital Ksk Holdings (3151) · InitiativeRestated
Distribution support for advanced medical care and new diagnostic and treatment methods
First written in FY2022. 2 of 3 entries say "Restated". Latest entry: FY2026.
3entries
5years
0from disclosures
How it moved
Same theme, other companies
Developing a healthcare distribution infrastructure for advanced medicine and diagnostic and treatment methodsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026RestatedAnnual report
「• Expanding sales of medical-related products」
The Group is reaffirming its policy of expanding into peripheral healthcare fields, including regenerative medicine, diagnostic agents, medical devices, and robots. - FY2025RestatedAnnual report
「• Expanding medical-related products」
The Group continues to address the distribution needs of peripheral healthcare fields, including regenerative medicine, diagnostic agents, medical devices, and robots, as an initiative under Long-Term Vision 2035. - FY2022First statedAnnual report
「In addition to regenerative medicine, new diagnostic and treatment methods, including new diagnostic agents, medical devices, and robots, are expected to drive future market growth while also creating new distribution-related challenges.」
The Group has identified addressing distribution challenges associated with new diagnostic and treatment methods, including regenerative medicine, diagnostic agents, medical devices, and robots, as a new theme arising from the market environment.